0000939767-23-000028.txt : 20230223
0000939767-23-000028.hdr.sgml : 20230223
20230223210812
ACCESSION NUMBER: 0000939767-23-000028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230221
FILED AS OF DATE: 20230223
DATE AS OF CHANGE: 20230223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garber Alan M
CENTRAL INDEX KEY: 0001312907
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 23662047
MAIL ADDRESS:
STREET 1: 3355 MILTON COURT
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94040
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_167720447178170.xml
FORM 4
X0306
4
2023-02-21
0
0000939767
EXELIXIS, INC.
EXEL
0001312907
Garber Alan M
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
1
0
0
0
Common Stock
2023-02-21
4
M
0
40000
6.30
A
71417
D
Common Stock
2023-02-21
4
S
0
40000
17.49
D
31417
D
Option (right to buy)
6.3
2023-02-21
4
M
0
40000
0
D
2016-05-26
2023-05-25
Common Stock
40000.0
0
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 2, 2022.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016.
/s/ Nina Ayer, Attorney in Fact
2023-02-23